

Contents

Introduction	1
1 Complement and Complement Reactions	5
1.1 The Components	5
1.1.1 Properties of the Components	5
1.1.2 Purification Procedures	17
1.1.2.1 Unified Protocol for Resolution of Complement Components from Inhibitor-Treated Plasma Using DEAE-Sephacel	19
1.1.2.2 Single Protocols for Purification of Individual Components	31
1.1.3 Complement Biosynthesis	44
1.1.3.1 Factors of the Classical Pathway	44
1.1.3.2 Factors of the Alternative Pathway	70
1.1.4 Genetics and Polymorphism of the Complement Components	80
1.1.4.1 Introduction	80
1.1.4.2 Methodology	80
1.1.4.3 C3 Polymorphism	87
1.1.4.4 C4 Polymorphism	93
1.1.4.5 Factor B Polymorphism (BF)	104
1.1.4.6 C2 Polymorphism	107
1.1.4.7 C5 Polymorphism in Man	109
1.1.4.8 C6 Polymorphism	110
1.1.4.9 C7 Polymorphism in Man	112
1.1.4.10 C81 (Alpha-Gamma) and C82 (Beta) Polymorphism in Man	113
1.1.4.11 Factor D in Man	114
1.1.4.12 Factor H Polymorphism in Man	115
1.1.4.13 C4BP Polymorphism	116
1.1.4.14 Factor I Polymorphism in Man	117
1.1.4.15 CR1 (C3b/C4b Receptor) Polymorphism in Man	117
1.1.4.16 Conclusions	119
1.2 Reactivity in Immune Hemolysis	136
1.2.1 "Classical" Pathway of Activation	136
1.2.1.1 Recognition Phase	137
1.2.1.2 Activation of the C1 Esterase, C1s	138
1.2.1.3 Formation of the C3/C5 Convertase (C4b, 2a)	141
1.2.1.4 Reactions of the Third Complement Component, C3	146
1.2.1.5 Reaction of the Fifth Complement Component, C5	148
1.2.2 Alternative Pathway of Activation	154
1.2.2.1 Introduction	154
1.2.2.2 Initiation of the Pathway	156
1.2.2.3 The Amplification C3 Convertase	159
1.2.2.4 The C5 Convertase	160
1.2.2.5 Control Mechanisms	161
1.2.2.6 Biological Role of the Alternative Pathway	163



1.2.3	Control Mechanisms	168
1.2.3.1	C1 Inhibitor	168
1.2.3.2	Regulation of the C3 Convertases	175
1.2.3.3	Regulation of the Late-Acting Components C5–C9	192
1.2.3.4	C1q Inhibitor (C1q-I)	195
1.2.3.5	Other Complement Inhibitors	196
1.2.4	Species-Dependent Incompatibilities	196
1.2.4.1	Incompatibility of Antibody with Complement	197
1.2.4.2	Incompatibilities Between Heterologous Components of the Classical Pathway	198
1.2.4.3	Incompatibilities Between Heterologous Components of the Alternative Pathway	200
1.2.4.4	Incompatibilities Between Regulatory Proteins and Heterologous Components	200
1.2.4.5	Incompatibilities of Complement Components with Target Cells	200
1.2.5	The Complement Attack Phase	202
1.2.5.1	Interaction of the Late Components with Each Other and with the Membrane	203
1.2.5.2	Complement-Mediated Killing of Nucleated Cells	213
1.2.5.3	Factors that Modulate the Efficiency of Complement-Mediated Damage	215
1.2.5.4	Other Biological Activities of the Late Complement Components	217
1.2.5.5	Innocent Bystander Lysis by C5–C9	230
1.2.6	Similarities Between Complement Lysis and Killing by Lymphocytes	237
1.2.6.1	Introduction	237
1.2.6.2	Direct Involvement of Complement Factors in Cell-Mediated Lysis	238
1.2.6.3	Kinetics and Stages of Lymphocyte-Mediated Killing	240
1.2.6.4	Recognition	241
1.2.6.5	Postbinding Events in CTL, ADCC, and NK	245
1.2.6.6	Additional or Alternative Putative Lytic Mechanisms	250
1.3	The Receptors	262
1.3.1	Introduction	262
1.3.2	Receptor for C1q	263
1.3.3	Receptor for a Fragment of C2	264
1.3.4	Receptors for Fragments of C4	264
1.3.5	Receptor for C3 Fragments	265
1.3.5.1	Receptor for C3a	265
1.3.5.2	Receptor for C3b (Complement Receptor 1, CR1)	265
1.3.5.3	Receptor for C3d, g and C3d (Complement Receptor 2, CR2)	267
1.3.5.4	Receptor for iC3b (Complement Receptor 3, CR3)	268
1.3.5.5	Receptor for C3e	268
1.3.5.6	Modulations of Receptors for C3 Fragments	268
1.3.6	Receptor for Factor H	269
1.3.7	Receptor for C5a	269
1.4	Complement Determinations in Clinical Diagnosis	272
1.4.1	Laboratory Complement Analysis	273
1.4.1.1	Screening Procedure	273
1.4.1.2	Disorders of the Classical Pathway	273
1.4.1.3	Complement Disorders Pointing to Disturbances of the Feedback Cycle of the Alternative Pathway and/or the Terminal Components	275
1.4.1.4	Conclusions	277
1.4.2	New Approaches to Evaluate Complement Activation	278
1.4.2.1	Assays for Quantitation of C1 Activation	278
1.4.2.2	Assays for Quantitating the Activation of the Alternative Pathway	279
1.4.2.3	Quantitation of the Fluid Phase Terminal Complex (SC5b–9)	280
1.4.2.4	Methods for Detecting Cleavage Products of Complement Components	280
1.4.2.5	Determination of the Anaphylatoxins C3a, C4a, and C5a	281
1.4.3	C1 Inhibitor Functional Test	281
1.4.4	Detection and Measurement of Free C1q	281
1.4.5	Detection and Estimation of Proenzyme C1r–C1s Complexes	282
1.4.6	Concluding Remarks	282

1.4.7	Demonstration of Complement Deposits in Tissue	287
1.4.7.1	Introduction	287
1.4.7.2	Physiological Deposition of Complement Components	288
1.4.7.3	Deposition of C Components Under Pathological Conditions	290
1.4.7.4	Pathogenetic Implications of C Activation In Situ	310
1.4.7.5	Technical Limitations of C Detection in Tissue	315
2	Biological Functions	327
2.1	Role of Complement in the Induction of Antibody Responses	327
2.1.1	Introduction	327
2.1.2	Role of Complement in Primary Antibody Responses	327
2.1.2.1	In Vitro Studies	327
2.1.2.2	In Vivo Studies	329
2.1.3	Role of C3 in the Generation of Immunological Memory	329
2.1.3.1	General Aspects	329
2.1.3.2	Importance of Antigen Trapping in Lymphoid Follicles	330
2.1.3.3	Mechanisms of Follicular Trapping	332
2.1.4	Concluding Remarks	333
2.2	Complement Interaction with Effector Cell Systems	337
2.2.1	Lysosomal Enzyme Release	337
2.2.2	Stimulation of Arachidonate Metabolism and Prostanoid Liberation by C3b, C3a, and Factor H	338
2.2.3	Reduction of Ia Antigens on Macrophages	339
2.2.4	Deactivation of Macrophages	341
2.3	Complement-Dependent Neutralization of Viruses	342
2.3.1	Introduction	342
2.3.2	Natural and Induced Immunity to Viruses and Virus-Infected Cells	343
2.3.3	Direct and Antibody-Dependent Complement Activation by Viruses and Virus-Infected Cells	344
2.3.4	Antibody and Complement-Dependent Viral Neutralization	345
2.3.5	Complement-Dependent Effects on Virus-Infected Cells	346
2.3.6	Conclusions	347
2.4	Leukocyte-Mobilizing Factor (LMF)	349
2.5	Chemotactic Factors	354
2.5.1	Introduction	354
2.5.2	Complement-Derived Chemotactic Factors	355
2.5.3	Trimolecular Complex of C567	356
2.5.4	C3-Derived Chemotactic Activity	357
2.5.5	C5-Derived Chemotactic Activity	360
2.5.6	Activity of the Alternative Complement Pathway	363
2.6	The Anaphylatoxins	367
2.6.1	Definition	367
2.6.2	Historical Survey	368
2.6.2.1	Phase 1	369
2.6.2.2	Phase 2	369
2.6.2.3	Phase 3	370
2.6.3	Present and Future	372
2.6.4	Chemical Structure	372
2.6.4.1	Carbohydrate Content	376
2.6.4.2	Antigenic Properties	376
2.6.4.3	Synthetic Peptides	377
2.6.4.4	Receptors	378
2.6.5	Biological Functions	380

2.6.5.1	Acute Respiratory Distress Syndrome	381
2.6.5.2	Anaphylatoxin-Peptide-Mediated Regulation of Humoral Immune Responses	382
2.6.6	In Vitro Test Systems	383
2.6.7	Conclusion	384
2.7	Opsonization, Phagocytosis, and Intracellular Microbial Killing	395
2.7.1	Introduction	395
2.7.2	Opsonization	395
2.7.3	Phagocytosis	398
2.7.3.1	Generation and Transmission of the Phagocytic Signal	398
2.7.3.2	Particle Ingestion	400
2.7.4	Cooperative Roles of Fc Receptors and Complement Receptors in Host Defense Against Microbial Infection	404
2.7.5	Intracellular Microbial Killing	407
2.7.6	Summary of the Roles of Complement Receptors in Opsonization, Phagocytosis, and Microbial Killing	408
2.8	Complement-Dependent Maintenance of Immune Complex Solubility	418
2.8.1	Introduction	418
2.8.2	Solubilization of Immune Aggregates by Complement	419
2.8.3	Inhibition of Precipitation by Complement	427
2.8.4	Nature of C3b and C4b Incorporation into Immune Complexes	432
2.8.5	Interaction of Immune Complexes with Cells: Role of Cell Membranes	433
2.8.6	Clinical Implications	439
3	Pathology	444
3.1	Complement-Deficient Animals	444
3.2	Disturbances of Control Mechanisms	451
3.2.1	Inherited and Acquired Deficiencies of C1 Esterase Inhibitor in Man	451
3.2.1.1	Introduction	451
3.2.1.2	Structural Properties of C1-INH	451
3.2.1.3	Procedures for Determination of C1-INH	452
3.2.1.4	Role of C1-INH in the Complement Cascade	453
3.2.1.5	Role of C1-INH in HF-Dependent Pathways	453
3.2.1.6	Inherited Deficiency of C1-INH of Man	453
3.2.1.7	Laboratory Diagnosis	454
3.2.1.8	Therapy	454
3.2.1.9	Acquired C1-INH Deficiency	454
3.2.2	Deficiencies of Factor I and Factor H	458
3.2.2.1	Introduction	458
3.2.2.2	First Factor I Deficient Patient: TJ	458
3.2.2.3	Other Patients with Factor I Deficiency	461
3.2.2.4	Factor H Deficiency	462
3.2.3	C3 Nephritic Factor	463
3.2.3.1	Studies on Whole Serum Containing C3NeF	463
3.2.3.2	Functional Studies of C3NeF	464
3.2.3.3	Studies on Purified C3NeF	466
3.3	Immunopathological Aspects of the Complement System	469
3.3.1	Defense Against Bacterial Infections	469
3.3.1.1	Introduction	469
3.3.1.2	Bactericidal Activity of Serum	470
3.3.1.3	Pathways of the Complement Activation by Bacteria	472
3.3.1.4	Resistance to Serum Bactericidal Activity	477
3.3.1.5	The Pathophysiological Significance of the Serum Bactericidal Activity and Serum Resistance of Bacteria	479
3.3.2	The Role of Complement in Immune Complex Induced Tissue Injury	487

3.3.2.1	Introduction	487
3.3.2.2	Experimental Models of Immune Complex Mediated Tissue Injury	489
3.3.2.3	Mediators in Immune Complex Tissue Injury	492
3.3.2.4	Conclusion	501
3.3.3	Shock and Shock Fragments	504
3.3.4	Adverse Reactions to Drugs	511
4	In Vivo Manipulation of the Complement System	520
4.1	Natural Proteinaceous Inhibitors	520
4.2	Simple Chemical Compounds	522
	Subject Index	525